Statistics

Total Visits

Views
Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab17

Select a period of time:

Number of views in the range

Views
Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab8

Views

Views
May 20241
June 20241
July 20243
August 20240
September 20243
October 20240
November 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States8
 

Top cities views

Views
Chicago1
Prineville1